{"name":"Atrogi AB","slug":"atrogi-ab","ticker":"","exchange":"","domain":"","description":"Atrogi AB is a biotechnology company focused on the development of innovative therapies. The company's lead candidate, ATR-258, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATR-258","genericName":"ATR-258","slug":"atr-258","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ATR-258","genericName":"ATR-258","slug":"atr-258","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBsMklZR3h5VU5PU0NueUtIV1g4U1FCbDY4X2JjYTRKWDczbUlkYk9aOWhnN1Q4V0xmWWdVa1hBei1xS0g0c2NuX3hveVZaQWxuWnA4VmdFY1Y2ckhONjdlc2ZrdzVsTExMa2FJckJsMA?oc=5","date":"2025-12-07","type":"pipeline","source":"ScienceDaily","summary":"New fat-burning diabetes pill protects muscle and appetite - ScienceDaily","headline":"New fat-burning diabetes pill protects muscle and appetite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNNF90d1lHb0RvdnJDcjdrQUVxMXh0elI2SzI5elZGdm0wZnFzVTM3d0NQdGpfZ0lUTUc2TmhtbEtMT1o5b2l2dDZFS0xZQVljNmQxVURPUWRPQmFEdTIwMkNSeUlMNkhlQjFER3NjeUdrSmdJVWltc2tLT0R1WTJQOGV2ZU1OcmlERmtyaTQzcWtYejA0WXVSRGRkNXU?oc=5","date":"2025-11-06","type":"pipeline","source":"BioCentury","summary":"Recursion picks J&J alum Khan to succeed Gibson as CEO - BioCentury","headline":"Recursion picks J&J alum Khan to succeed Gibson as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOTFlZandpczhrbi1peVRNQkVPWk1TUUM4cTNYYU9IYWo2aG80WmUyOTZQRHdnWTlXeGRLS283MGNmcVMxNjAzaHlrRUs1ZTJWZTlGcGl4aTMyN3FVOXpnNjhLWXQybTczYTBZT3NNZ19fSXBaUEx1REZvaVRRN0FIbW1JdXNkN0xTUS1Vc0JMSnYyb1BWc3NIc2hNbkhOYjA0OEJxU05JYlp0MjNNZ2g5LXZOQjhqd2hXVldqWVhPNUctZzlTdHFn?oc=5","date":"2025-06-23","type":"pipeline","source":"News-Medical","summary":"New oral drug shows promise for type 2 diabetes and obesity without side effects - News-Medical","headline":"New oral drug shows promise for type 2 diabetes and obesity without side effects - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQR1RzaU8zTmdWU0loU2VLX3VnWGhXQWdGQUlod0R4VV92SjdwdFlBRDFIWDdaSzE3TG5ORk5sbE5mRU9iYm50bk5fTXE4U2ZLMlVZOXd5bml6U1JvaTlrV2Z3T1RjSDlfRTdpQ3ZDeUt3RURPNGhnVHo0b0tMOW5vSXM4T21VcUV5?oc=5","date":"2023-01-26","type":"trial","source":"Labiotech.eu","summary":"First patient treated in Atrogi type 2 diabetes clinical study - Labiotech.eu","headline":"First patient treated in Atrogi type 2 diabetes clinical study","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}